Jantine PosthumaDeBoer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jantine PosthumaDeBoer has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
B.J. van Royen
1 shared publication- Barend J. van Royen
Department of Orthopaedic Surgery, VU University Medical Center, Amsterdam, The Netherlands
1 shared publication - Gertjan Johannes Laurentius Kaspers
Emma Children's Hospital Amsterdam UMC Vrije Universiteit Amsterdam Amsterdam The Netherlands
1 shared publication - Harm Ca Graat
Department of Orthopaedic Surgery, VU University Medical Center, PO box 7057, 1007 MB Amsterdam, the Netherlands
1 shared publication - Harm Ca Graat
Department of Orthopaedic Surgery, VU University Medical Centre, Amsterdam., The Netherlands
1 shared publication - Johannes Bras
Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Herbert Publications PVT LTD in Oncology Discovery
- Vol. 1 (1) , 8
Mechanisms of therapy resistance in osteosarcoma: a review
Therapy resistance remains a challenge in the treatment for osteosarcoma (OS). By studying therapy resistance and gaining biological understanding of resistance in OS, novel treatment targets to sensitise OS could potentially
- 1 January 2013
- Published by Herbert Publications PVT LTD in Oncology Discovery
- Vol. 1 (1) , 8
Open AccessMechanisms of therapy resistance in osteosarcoma: a review
Therapy resistance remains a challenge in the treatment for osteosarcoma (OS). By studying therapy resistance and gaining biological understanding of resistance in OS, novel treatment targets to sensitise OS could potentially
- Open Access
- 29 April 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 156
WEE1 inhibition sensitizes osteosarcoma to radiotherapy
Background: The use of radiotherapy in osteosarcoma (OS) is controversial due to its radioresistance. OS patients currently treated with radiotherapy generally are inoperable, have painful skeletal metastases, refuse surgery or have undergone an intralesional resection of the primary tumor. After irradiation-induced DNA damage, OS cells sustain a prolonged G2cell cycle checkpoint arrest allowing DNA repair and evasion of cell death. Inhibition of WEE1 kinase leads to abrogation of the G2arrest and could sensitize OS cells to irradiation induced cell death.Methods: WEE1 expression in OS was investigated by gene-expression data analysis and immunohistochemistry of tumor samples. WEE1 expression in OS cell lines and human osteoblasts was investigated by Western blot. The effect of WEE1 inhibition on the radiosensitivity of OS cells was assessed by cell viability and caspase activation analyses after combination treatment. The presence of DNA damage was visualized using immunofluorescence microscopy. Cell cycle effects were investigated by flow cytometry and WEE1 kinase regulation was analyzed by Western blot.Results: WEE1 expression is found in the majority of tested OS tissue samples. Small molecule drug PD0166285 inhibits WEE1 kinase activity. In the presence of WEE1-inhibitor, irradiated cells fail to repair their damaged DNA, and show higher levels of caspase activation. The inhibition of WEE1 effectively abrogates the irradiation-induced G2arrest in OS cells, forcing the cells into premature, catastrophic mitosis, thus enhancing cell death after irradiation treatment.Conclusion: We show that PD0166285, a small molecule WEE1 kinase inhibitor, can abrogate the G2checkpoint in OS cells, pushing them into mitotic catastrophe and thus sensitizing OS cells to irradiation-induced cell death. This suggests that WEE1 inhibition may be a promising strategy to enhance the radiotherapy effect in patients with OS.
- 29 April 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 156
Open AccessWEE1 inhibition sensitizes osteosarcoma to radiotherapy
Background: The use of radiotherapy in osteosarcoma (OS) is controversial due to its radioresistance. OS patients currently treated with radiotherapy generally are inoperable, have painful skeletal metastases, refuse surgery or have undergone an intralesional resection of the primary tumor. After irradiation-induced DNA damage, OS cells sustain a prolonged G2cell cycle checkpoint arrest allowing DNA repair and evasion of cell death. Inhibition of WEE1 kinase leads to abrogation of the G2arrest and could sensitize OS cells to irradiation induced cell death.Methods: WEE1 expression in OS was investigated by gene-expression data analysis and immunohistochemistry of tumor samples. WEE1 expression in OS cell lines and human osteoblasts was investigated by Western blot. The effect of WEE1 inhibition on the radiosensitivity of OS cells was assessed by cell viability and caspase activation analyses after combination treatment. The presence of DNA damage was visualized using immunofluorescence microscopy. Cell cycle effects were investigated by flow cytometry and WEE1 kinase regulation was analyzed by Western blot.Results: WEE1 expression is found in the majority of tested OS tissue samples. Small molecule drug PD0166285 inhibits WEE1 kinase activity. In the presence of WEE1-inhibitor, irradiated cells fail to repair their damaged DNA, and show higher levels of caspase activation. The inhibition of WEE1 effectively abrogates the irradiation-induced G2arrest in OS cells, forcing the cells into premature, catastrophic mitosis, thus enhancing cell death after irradiation treatment.Conclusion: We show that PD0166285, a small molecule WEE1 kinase inhibitor, can abrogate the G2checkpoint in OS cells, pushing them into mitotic catastrophe and thus sensitizing OS cells to irradiation-induced cell death. This suggests that WEE1 inhibition may be a promising strategy to enhance the radiotherapy effect in patients with OS.
- Open Access
- 1 January 2010
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 5 (1) , 36
Small cell osteosarcoma of a toe phalanx: a case report and review of literature
This report describes the radiological and histological findings of a small cell osteosarcoma of a toe phalanx in a 38 year old man. This man presented with pain, swelling and redness of the left third toe. Medical history revealed an osteomyelitis of this toe eight years prior. Based on clinical findings and medical history the lesion was diagnosed as an osteomyelitis. However, peroperatively the lesion had a malignant aspect. Histological examination revealed a small cell osteosarcoma of the proximal phalanx.
- 1 January 2010
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 5 (1) , 36
Open AccessSmall cell osteosarcoma of a toe phalanx: a case report and review of literature
This report describes the radiological and histological findings of a small cell osteosarcoma of a toe phalanx in a 38 year old man. This man presented with pain, swelling and redness of the left third toe. Medical history revealed an osteomyelitis of this toe eight years prior. Based on clinical findings and medical history the lesion was diagnosed as an osteomyelitis. However, peroperatively the lesion had a malignant aspect. Histological examination revealed a small cell osteosarcoma of the proximal phalanx.